ニュース、リソース、最新情報
当社の最新の研究動向や企業情報をお届けする科学情報拠点です。
InnoSerが、Eurostarsの資金提供を受けるプロジェクト「LEMONAID」に参加
LEMONAID takes on the challenge of developing a new drug against Diffuse Large B-Cell Lymphoma (DLBCL) tumors to ultimately reduce drug resistance and relapse potential for patients. InnoSer supports this ambition by its expertise in combined in-vitro and in-vivo...
InnoSerは「成長のための知識」イベントで皆様をお迎えします
[EDIT]: This event is now hold digitally, and we are looking forward to talking to you at one of our virtual meetings. Detailed schedules to be announced soon! Organized by flanders.bio since it's establishment in 2004, knowledge for growth brings over 1300 biotech,...
InnoSerは、ウィム・ティエスト氏を最高技術責任者（CTO）として迎えました
As of April 2020, Wim Tiest has joined InnoSer in the role of Chief Technology Officer (CTO) and as part of the company management team. Wim holds a MSc in biochemical engineering and in artificial intelligence, both from the KU Leuven. He has built his professional...
InnoSerにおけるPDX/O腫瘍学プラットフォームの開発状況
Despite the challenging times for the life sciences sector during coronavirus restrictions, we’ve been fortunate enough and well prepared to continue with the development of our PDX/O platform for oncology research. On a weekly basis we receive patient tumor samples...
プレスリリース：InnoSerは、重要な生体内および生体外試験サービスを提供し続けています
Press release | Leiden, 19 March 2020InnoSer continues to deliver critical in-vivo and in-vitro services COVID-19 restrictions call for attention to prevent fully halting life sciences operationsInnoSer remains committed to continuing its in-vivo and in-vitro research...
新型コロナウイルス感染症への予防策
Following the most recent governmental advice and regulations, we have decided to take preventative measures against the fast spread of COVID-19. The health and interests of our customers, employees and other stakeholders are our top priority. In order to minimize the...
info@innoserlaboratories.com